BioCentury | Feb 29, 2016
Clinical News

SOR-C13: Phase I data

...all previous anticancer treatments in an open-label, North American Phase I trial showed that IV SOR-C13...
...patients with advanced pancreatic cancer had reductions in tumor size of 7% and 27%, respectively. SOR-C13...
...No treatment-related serious adverse events were reported. Soricimed Biopharma Inc. , Moncton, New Brunswick Product: SOR-C13...
BioCentury | Jan 18, 2016
Clinical News

SOR-C13: Completed Phase I enrollment

...enrollment of 23 patients in an open-label, dose-escalation, North American Phase I trial evaluating IV SOR-C13...
...days 1-3 and 8-10 in 21-day cycles. Soricimed Biopharma Inc. , Moncton, New Brunswick Product: SOR-C13...
BioCentury | Aug 20, 2012
Clinical News

SOR-C13: Phase I started

...Soricimed began an open-label, dose-escalation, North American Phase I trial to evaluate IV SOR-C13 given on...
...known to express the TRPV6 ion channel. Soricimed Biopharma Inc. , Moncton, New Brunswick Product: SOR-C13...
Items per page:
1 - 3 of 3